review of control strategy of gmp march 2014
TRANSCRIPT
![Page 1: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/1.jpg)
Review of Control Strategy of GMP
Obaid Ali & Roohi B. Obaid (March 2013)
![Page 2: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/2.jpg)
Disclaimer and References
The views expressed in this presentation are not necessarily of the Drug Regulatory Authority of Pakistan
It is an informal communication that represents the best current judgment and does not constitute an advisory opinion or binding or otherwise obligate or commit the DRAP, to the views expressed.
This presentation is designed by the speaker after consulting international reference documents
![Page 3: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/3.jpg)
Presentation Focus
Cont’d
![Page 4: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/4.jpg)
Presentation Focus
![Page 5: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/5.jpg)
Back mirror challenges; Wake up call….s
![Page 6: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/6.jpg)
![Page 7: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/7.jpg)
![Page 8: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/8.jpg)
Regulatory Complexity
![Page 9: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/9.jpg)
Why Regulations?
![Page 10: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/10.jpg)
Its not just as simple as its seems to be
![Page 11: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/11.jpg)
![Page 12: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/12.jpg)
![Page 13: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/13.jpg)
Pre-approval Inspection
Post-approval Inspection
Pre-market Review
Post-market Review
SCENE
Regulatory Background
D R U
G
![Page 14: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/14.jpg)
SCENE
Very near to your and your beloved one’s lives
Very near to your and your beloved one’s lives
Health care profession and business
Health care profession and business
Regulations
protect
and
promote
Public Health
![Page 15: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/15.jpg)
New
Generics
Primary Logical Boundaries
D R U G S
![Page 16: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/16.jpg)
New Drugs
Main Concerns
Safety
Effi
cacy
Clinical SitesS
uppl
y C
hain Vigilance
Manufacturing Site
![Page 17: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/17.jpg)
1
Main Elements of Review Process for New Drugs
Toxicology & Pharmacology
Clinical Pharmacol & Bio-Pharmaceutics
Medical & StatisticalImmunological review esp. for BiologicalsChemistry & CMC
Risk Evaluation & Mitigation Strategy
234
56
SCENE
5
Cross Discipline7
![Page 18: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/18.jpg)
CONCERNS
CMC review….. SMF, DMF, LIF………..CMC review….. SMF, DMF, LIF………..
SCENE
Generic or
approved
new Drug
for new site
New Drug
Main Elements of Review Process for Generic Drugs
Clinical study….Bio-studies….Dissolution studies………Justification of waiverClinical study….Bio-studies….Dissolution studies………Justification of waiver
Labeling review……Product Development……Stability……..Shelf lifeLabeling review……Product Development……Stability……..Shelf life
Manufacturing capacity………Pre-approval Inspection report………..history of GMPManufacturing capacity………Pre-approval Inspection report………..history of GMP
![Page 19: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/19.jpg)
Review Journey
ProcessDesign
Review
SCENE
Mee
tings
Writing
![Page 20: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/20.jpg)
SCENE
Review Model of the 21st Century
CTD International
Conference on Harmonization
Question based review
![Page 21: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/21.jpg)
Main Challenges
ABILITY
Data Analysis and Assessment
SCENE
Iden
tific
atio
n of
Dat
a G
enui
nene
ss
Report W
riting
![Page 22: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/22.jpg)
![Page 23: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/23.jpg)
Consistency, mix-up, Contamination, Cross-contamination, Traceability and Data Integrity
![Page 24: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/24.jpg)
Quality can not be observed by every one and/or by naked eye or even by product testing.
![Page 25: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/25.jpg)
………………..triggered a serious adverse reaction by depositing itself in the bone marrow and ending the body's resistance. The generation of white blood cells stopped in the body. Among the symptoms of the disease were change in skin color/pigmentation, low platelet count and blood vomiting.
………………..triggered a serious adverse reaction by depositing itself in the bone marrow and ending the body's resistance. The generation of white blood cells stopped in the body. Among the symptoms of the disease were change in skin color/pigmentation, low platelet count and blood vomiting.
Recall the painful memories
![Page 26: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/26.jpg)
Good Manufacturing Practice is the only and absolute answer to
ensure product quality of drug for approved drugs
Good Manufacturing Practice is the only and absolute answer to
ensure product quality of drug for approved drugs
![Page 27: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/27.jpg)
Regulatory Mandate
………GMP under Schedule B……..
Obligatory to comply
Regulatory Mandate
………GMP under Schedule B……..
Obligatory to comply
![Page 28: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/28.jpg)
GMP Expectations
![Page 29: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/29.jpg)
Is the drug consistent to each other
Is it mix up free
Is it not contaminated
Is it not cross-contaminated
Is data and manufacturing history traceable
Is data reliable and genuine...........
![Page 30: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/30.jpg)
![Page 31: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/31.jpg)
Variations play ?????
Variations play ?????
![Page 32: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/32.jpg)
Mix-upA number of drug products are being manufactured in a
same manufacturing facility
Label mix upPowder mix upBulk product mix upIn-process mix upBlister mix up Etc.
![Page 33: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/33.jpg)
Let’s make science visible
![Page 34: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/34.jpg)
![Page 35: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/35.jpg)
![Page 36: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/36.jpg)
![Page 37: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/37.jpg)
![Page 38: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/38.jpg)
Case Studies
![Page 39: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/39.jpg)
Unknown peak in Misoprostol
Unknown peak identified in 13 lots of Cytotec tablet
A delayed (after 1.5 months) internal investigation report suggested contamination
during handling but it was unknown contaminant
![Page 40: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/40.jpg)
Investigation Failure at QCU
Another investigation after 1.5 years suggested (based on relative retention time) the unknown
contaminant as toluene
![Page 41: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/41.jpg)
Investigation Failure at QCU
After 1.5 years internal evaluation revealed the probable source of toluene was related to loose ink
in blister packaging line
Firm did not considered it as a foreign substance and argued that toluene is also used in chemical
synthesis of misoprostol oil. It was a hypothesis, no record was available
![Page 42: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/42.jpg)
Investigation Failure at QCU
Not a single cause out of both could be assigned, whether it was a residue from API or improper
packaging
There was no evidence that toluene is being monitored during the stability of API
Not a single cause out of both could be assigned, whether it was a residue from API or improper
packaging
There was no evidence that toluene is being monitored during the stability of API
![Page 43: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/43.jpg)
Investigation Failure at QCU
Diethylphthalate (DEP) can be a source of contamination from desiccant cartridge
![Page 44: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/44.jpg)
J&JDec 2009
Several complaints of uncharacteristic strong odor were received to J&J from 2008 to 2009 for their several OTC products packaged in bottles.
J&J failed to conduct a timely, comprehensive investigation, determine and assign a root cause
![Page 45: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/45.jpg)
J&JDec 2009
The adverse event was reported as gastrointestinal distress
This lead to recall of several lots of Tylenol Arthritis Relief Caplets and several other OTC
products
![Page 46: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/46.jpg)
J&JDec 2009
The reason was a pesticide 2,4,6 Tribromophenol (TBP) sprayed on wooden
pallets used to keep finished products during shipping
This pesticide degraded to 2,4,6 Tribromoanisole (TBA) with a musty odor
contaminating product containers and finished product in those containers
![Page 47: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/47.jpg)
Pfizer 2010Pfizer 2010
Several lots of Lipitor (191, 000 bottles)were recalled due to the same reason. i.e. unusual odor/ moldy smell of 2,4,6 Tribromoanisole, a degradant of TBP used to disinfect wooden
pallets
Several lots of Lipitor (191, 000 bottles)were recalled due to the same reason. i.e. unusual odor/ moldy smell of 2,4,6 Tribromoanisole, a degradant of TBP used to disinfect wooden
pallets
![Page 48: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/48.jpg)
GSK June 2011GSK June 2011
A huge recall of Augmentin syrup in China, Hong Kong etc. contaminated with di-isodecyl
phthalate (DIDP) Plasticizer ordered by Chinese SFDA
A huge recall of Augmentin syrup in China, Hong Kong etc. contaminated with di-isodecyl
phthalate (DIDP) Plasticizer ordered by Chinese SFDA
![Page 49: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/49.jpg)
GSK June 2011GSK June 2011
According to Chinese SFDA, the drug was tainted with the DIDP plasticizer which is used
to make the plastic more flexible
ResultA huge number of bottles were recalled
According to Chinese SFDA, the drug was tainted with the DIDP plasticizer which is used
to make the plastic more flexible
ResultA huge number of bottles were recalled
![Page 50: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/50.jpg)
Ranbaxy 2008Batamandi
Ranbaxy 2008Batamandi
Cleaning record of the equipment V-blender contained signature of employees who
verified the cleaning of equipment, but were not actually present at that particular time
Cleaning record of the equipment V-blender contained signature of employees who
verified the cleaning of equipment, but were not actually present at that particular time
![Page 51: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/51.jpg)
Ranbaxy 2008Batamandi
Ranbaxy 2008Batamandi
This came to bright through security log records used to control the entry of all
personnel entering or exiting the facility
This came to bright through security log records used to control the entry of all
personnel entering or exiting the facility
![Page 52: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/52.jpg)
Ranbaxy 2008Batamandi
Ranbaxy 2008Batamandi
The security log records showed that the persons/supervisors who signed the “Checked by Production Executive or
“Cleared by QA Executive” were not present at the facility on the days equipment was
cleaned
The security log records showed that the persons/supervisors who signed the “Checked by Production Executive or
“Cleared by QA Executive” were not present at the facility on the days equipment was
cleaned
![Page 53: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/53.jpg)
Ranbaxy 2008Batamandi
Ranbaxy 2008Batamandi
Furthermore, the employee of the firm believed that his physical presence was not necessary
during the activity and he can sign off by asking someone to bring records to him for signature on the batch records as to have checked the
activity
Furthermore, the employee of the firm believed that his physical presence was not necessary
during the activity and he can sign off by asking someone to bring records to him for signature on the batch records as to have checked the
activity
![Page 54: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/54.jpg)
Ranbaxy 2008Batamandi
Ranbaxy 2008Batamandi
This demonstrates the lack of understanding of the fundamental purpose of independent
verification under cGMP. Such verification is paramount to ensure that
procedures or works are adequately performed to reduce the risk of human error
This demonstrates the lack of understanding of the fundamental purpose of independent
verification under cGMP. Such verification is paramount to ensure that
procedures or works are adequately performed to reduce the risk of human error
![Page 55: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/55.jpg)
Ranbaxy 2008Batamandi
Ranbaxy 2008Batamandi
Incomplete or compromised cleaning of equipment can provide a way for cross-
contamination or inadvertent contamination of drug products with residual cleaning agents
or solvents
Incomplete or compromised cleaning of equipment can provide a way for cross-
contamination or inadvertent contamination of drug products with residual cleaning agents
or solvents
![Page 56: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/56.jpg)
Ranbaxy 2008Batamandi
Ranbaxy 2008Batamandi
The deficiencies in equipment cleaning and batch production and control records threaten the concerns related to the
conduct, adequacy and oversight of Quality System of the firm especially the integrity
and reliability of records
The deficiencies in equipment cleaning and batch production and control records threaten the concerns related to the
conduct, adequacy and oversight of Quality System of the firm especially the integrity
and reliability of records
![Page 57: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/57.jpg)
Ranbaxy 2008 Dewas
Ranbaxy 2008 Dewas
Persons from QC moved freely collecting samples between beta-lactam and non-beta-
lactam manufacturing blocks
Persons from QC moved freely collecting samples between beta-lactam and non-beta-
lactam manufacturing blocks
![Page 58: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/58.jpg)
Ranbaxy 2008 Dewas
Ranbaxy 2008 Dewas
Persons working in beta-lactam API warehouses were moving freely on the
manufacturing campus
Persons working in beta-lactam API warehouses were moving freely on the
manufacturing campus
![Page 59: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/59.jpg)
Ranbaxy 2008 Dewas
Ranbaxy 2008 Dewas
Persons working in beta-lactam API warehouses were moving freely on the
manufacturing campus
Persons working in beta-lactam API warehouses were moving freely on the
manufacturing campus
![Page 60: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/60.jpg)
Ranbaxy 2008 Dewas
Ranbaxy 2008 Dewas
Persons working in Cephalosporin API dispensing area were observed with powder on their gowns and coming in direct contact
with outer surface of a bulk material bag that was placed on transport equipment that can
enter in non-beta-lactam areas
Persons working in Cephalosporin API dispensing area were observed with powder on their gowns and coming in direct contact
with outer surface of a bulk material bag that was placed on transport equipment that can
enter in non-beta-lactam areas
![Page 61: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/61.jpg)
Ranbaxy 2008 Dewas
Ranbaxy 2008 Dewas
Surface monitoring (sampling/testing) for residual traces of penicillin type beta-lactams is
not performed in the Penem Block where penem sterile parenterals are manufactured or in Block where multiple cephalosporin finished
products are manufactured.
Surface monitoring (sampling/testing) for residual traces of penicillin type beta-lactams is
not performed in the Penem Block where penem sterile parenterals are manufactured or in Block where multiple cephalosporin finished
products are manufactured.
![Page 62: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/62.jpg)
Ranbaxy 2008 Dewas
Ranbaxy 2008 Dewas
Surface monitoring for residual traces of cephalosporin type beta-lactams is not performed in the General Block where
multiple non-beta-lactam finished products are manufactured or in the Penem Block
where sterile parenterals are manufactured.
Surface monitoring for residual traces of cephalosporin type beta-lactams is not performed in the General Block where
multiple non-beta-lactam finished products are manufactured or in the Penem Block
where sterile parenterals are manufactured.
![Page 63: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/63.jpg)
Ranbaxy 2008 Dewas
Ranbaxy 2008 Dewas
Result of such observationsConsent Decree and Import Alert for their
products in USA until drugs can be manufactured in the facilities complying with US manufacturing
Quality Standards
Result of such observationsConsent Decree and Import Alert for their
products in USA until drugs can be manufactured in the facilities complying with US manufacturing
Quality Standards
![Page 64: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/64.jpg)
Human Factor Analysis and Classification System
![Page 65: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/65.jpg)
What considerations will enhance preventive system and control?
![Page 66: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/66.jpg)
![Page 67: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/67.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 68: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/68.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 69: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/69.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 70: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/70.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 71: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/71.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 72: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/72.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 73: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/73.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 74: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/74.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 75: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/75.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 76: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/76.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 77: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/77.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 78: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/78.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 79: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/79.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 80: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/80.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 81: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/81.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 82: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/82.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 83: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/83.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 84: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/84.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 85: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/85.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 86: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/86.jpg)
Human Factor Analysis & Classification System (HFACS)
![Page 87: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/87.jpg)
Human Factor Analysis & Classification System (HFACS)
“………records are not completed
contemporaneously”
“………records are not completed
contemporaneously”
Misguided
Malicious
![Page 88: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/88.jpg)
Closing Message SCENE
If there is a will, there is a way
![Page 89: Review of Control Strategy of GMP March 2014](https://reader034.vdocuments.us/reader034/viewer/2022051315/55a605e31a28abed248b462a/html5/thumbnails/89.jpg)
If everyone is moving forward together, then success takes care of itself
(Henry Ford)
If everyone is moving forward together, then success takes care of itself
(Henry Ford)